Abstracts Archive - Page 541 of 2607 - ACR Meeting Abstracts

Abstract Number: 121 • 2023 Pediatric Rheumatology Symposium
The Effectiveness of Tonsillectomy in Periodic Fever, Aphthous Ulcer, Pharyngitis, and Adenitis Syndrome in Pediatric Patients
John Storwick¹ and Marinka Twilt², ¹Alberta Children's Hospital/University of Calgary, Calgary, AB, Canada, ²Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Periodic Fevers with Aphthous Ulcers, Pharyngitis, and Adenitis Syndrome (PFAPA Syndrome) is the most common pediatric periodic fever syndrome. The most recent diagnostic criteria…
Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium
Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Alysha Taxter¹, Marc Natter², Min-Lee Chang², Laura Schanberg³, Valarie Morrow⁴, Eveline Wu⁵, Tedryl Bumpass⁴, Alex Fist⁴, Meg Waite⁶, Vincent Del Gaizo⁷, Melanie Kohlheim⁷ and CARRA Registry Investigators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Boston Children's Hospital, Boston, MA, ⁷CARRA, Washington, DC
Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…
Abstract Number: 124 • 2023 Pediatric Rheumatology Symposium
JIA-Associated TMJ Arthritis, Idiopathic Condylar Resorption or Anterior Disc Displacement – a Care Provider Survey
Daria Sosna¹, Nancy Pan², Shelly Abramowicz³, Mara Becker⁴, Melissa Lerman⁵, Cory Resnick⁶, Tova Ronis⁷, Matthew Stoll⁸, Peter Stoustrup⁹, Marinka Twilt¹⁰, CARRA Registry Investigators¹¹ and For TMJaw¹², ¹Alberta Children's Hospital/University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York, NY, ³Emory University, Atlanta, GA, ⁴Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Harvard University, Boston, MA, ⁷Children's National Hospital, Chevy Chase, MD, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Aarhus University, Aarhus, Denmark, ¹⁰Alberta Children's Hospital, Calgary, AB, Canada, ¹¹CARRA, Washington, DC, ¹²TMJaw, Fullerton, CA
Background/Purpose: The temporomandibular joint (TMJ) can be affected in juvenile idiopathic arthritis (JIA) patients of any age or subtype. There have been reports of isolated…
Abstract Number: 127 • 2023 Pediatric Rheumatology Symposium
What’s in a Name? A20 Protein Expression in an in Vitro Model of A20 Haploinsufficiency
Patricia Pontes Aires¹, DANIELA GERENT PETRY PIOTTO¹, Andre Cunha¹, Sandro Perazzio² and Maria Teresa Terreri³, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidade de So Paulo; Fleury Laboratories, São Paulo, Brazil, ³UNIFESP, São Paulo, Brazil
Background/Purpose: Tumor necrosis factor alpha (TNF-alpha) induced protein 3 gene, or TNFAIP3, encodes the A20 protein, an important regulator of the NF-κB pathway. Since its…
Abstract Number: 126 • 2023 Pediatric Rheumatology Symposium
Facilitating Peer-to-Peer Conversations Around Key Clinical Trial Recruitment Barriers in the Limit-JIA Trial Using Low-Fidelity Video Capture
Melanie Kohlheim¹, Eveline Wu², Laura Schanberg³, Vincent Del Gaizo¹, Catherine Lavallee⁴, Marc Natter⁵, Katie Clem⁶, Brian Shakley⁶ and Kevin Urban⁷, ¹CARRA, Washington, DC, ²UNC Chapel Hill, Chapel Hill, NC, ³Duke University Medical Center, Durham, NC, ⁴Virginia Tech Carilion School of Medicine, ROANOKE, VA, ⁵Boston Children's Hospital, Boston, MA, ⁶LIFT 1428, Llc, Ooltewah, TN, ⁷Business Coaching for Creatives, New York, NY
Background/Purpose: The LIMIT-JIA trial aims to study if early abatacept treatment can prevent disease extension in children with recent-onset, uncomplicated, and oligoarticular or limited JIA.…
Abstract Number: 133 • 2023 Pediatric Rheumatology Symposium
An Interdisciplinary Team Approach to Implementation of a Social Determinants of Health Screener for Pediatric Rheumatology Patients
Sarah Campbell¹, Rosemary Peterson², Sarah Barrientos³, Elinore Benett³ and Cori Christenholz³, ¹University of Texas at Austin Dell Medical School, Austin, TX, ²Dell Medical School at UT Austin, Austin, TX, ³Dell Children's Medical Center Department of Rheumatology, Austin, TX
Background/Purpose: Adolescents with chronic disease often struggle with the transition from pediatric to adult healthcare leading to poor follow-up and negative health outcomes. Social determinants…
Abstract Number: 132 • 2023 Pediatric Rheumatology Symposium
Quality Improvement Lessons in a New Practice
Farah Shaya, Sharon Bout-Tabaku and Buthaina Al-Adba, Sidra Medicine, Ar-Rayyan, Qatar
Background/Purpose: Children with Juvenile Idiopathic Arthritis (JIA) have better disease outcomes with current medications available, yet there is variability in these outcomes. Quality improvement (QI)…
Abstract Number: 125 • 2023 Pediatric Rheumatology Symposium
Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic
Catherine Lavallee¹, Sabrina Gmuca² and Melissa Lerman², ¹Virginia Tech Carilion School of Medicine, ROANOKE, VA, ²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Non-infectious pediatric uveitis is a vision threatening disease whose treatment involves both ophthalmologists and rheumatologists.In other diseases necessitating multidisciplinary care, coordinated care clinics have…
Abstract Number: 129 • 2023 Pediatric Rheumatology Symposium
Interrogation of STAT3 Activation in Patients with Polyarticular Juvenile Arthritis (polyJIA)
Stephanie Wood¹, Justin Branch¹, Priscilla vasquez¹, Marietta De Guzman¹, Amanda Brown², A. Carmela Sagcal-Gironella³, Saimun Singla⁴, Andrea Ramirez⁵ and Tiphanie Vogel⁵, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Hackensack University Medical Center, Hackensack, NJ, ⁴Self, Houston, TX, ⁵Baylor College of Medicine, Houston, TX
Background/Purpose: A better understanding of the pathogenesis of polyJIA is necessary to guide more effective clinical care, such as the development of data-driven approaches to…
Abstract Number: 135 • 2023 Pediatric Rheumatology Symposium
Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative
Dori Abel¹, Joyce Chang², Jon Burnham³, Chen Kenyon⁴ and Sabrina Gmuca⁵, ¹Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ²Boston Children's Hospital, Boston, MA, ³Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; PolicyLab, Children’s Hospital of Philadelphia, Philadelphia, PA; Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Center for Pediatric Clinical Effectiveness, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used…
Abstract Number: 131 • 2023 Pediatric Rheumatology Symposium
Improving Methotrexate Documentation in Electronic Health Records – a Quality Improvement Initiative
Jayne MacMahon¹, Jeanine McColl², Alaa Al-Shehab¹, Deborah Levy³, Ronald laxer¹ and Shirley Tse¹, ¹University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ²University of Alberta, Edmonton, AB, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Prescribing methotrexate,is common practice in rheumatology. Appropriate medication counselling and documentation is important. In our province, as per thephysician regulatory body the College of…
Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Beatriz Carneiro¹, Adriana Elias¹, Teresa Robazzi², Ana Julia Moraes³, Sheila Oliveira⁴, Flavio Sztajnbok⁵, Luciana Carvalho⁶, Luciana Marques⁷, Silvana Sacchetti⁸, Maria Teresa Terreri⁹, Simone Appenzelle¹⁰, Roberto Marini¹¹, Andre Cavalcante¹², Marcia Bandeira¹³, Cristina Magalhaes¹⁴, Melissa Fraga¹⁵, Iloite Scheibel¹⁶, Isabela Daud¹, Darcisio Antonio¹⁷, Claudio Len¹⁸, Clovis Silva¹⁹, Taciana Fernandes¹⁷ and Claudia Magalhaes²⁰, ¹Instituto da Criança - Universidade de São Paulo (USP), São Paulo, Brazil, ²Universidade Federal da Bahia, Brazil, ³Universidade Federal do Para, Brazil, ⁴Universidade Federal do Rio de janeiro, Rio de Janeiro, ⁵Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Universidade de Sao Paulo- Ribeirao Preto, São Paulo, Brazil, ⁷Hospital Albert Sabin, Brazil, ⁸Santa Casa de Sao Paulo, Brazil, ⁹UNIFESP, São Paulo, Brazil, ¹⁰University of Campinas, Campinas, Sao Paulo, Brazil, ¹¹UNICAMP, São Paulo, Brazil, ¹²Hospital Materno-Infantil de Goiania, Brazil, ¹³Hospital Pequeno Principe- Curitiba, Brazil, ¹⁴Hospital Jose de Alencar - Brasilia, Brazil, ¹⁵Hospital Darcy Vargas, Brazil, ¹⁶Hospital Conceição de Porto Alegre, Brazil, ¹⁷Universidade Estadual Paulista (UNESP) Botucatu, Brazil, ¹⁸Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, ¹⁹Universidade de São Paulo, São Paulo, Brazil, ²⁰São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…
Abstract Number: 130 • 2023 Pediatric Rheumatology Symposium
Levels of Neutrophil Extracellular Traps Correlate with Disease Activity in Pediatric Lupus
Lydia Thomas¹, Jenna Battaglia², Bharati Matta³, Kim Simpfendorfer⁴, Joyce Hui-Yuen⁵ and Betsy Barnes³, ¹Cohen Children's Medical Center, Northwell Health, New Hyde Park, NY, ²Northwell Health, New York, NY, ³Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁴Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁵Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
Background/Purpose: Pediatric lupus (pSLE) is a multisystemic autoimmune disease characterized by autoantibody production leading to organ damage. Neutrophil extracellular traps (NETs) are considered a potential…
Abstract Number: 137 • 2023 Pediatric Rheumatology Symposium
Geographic Mapping of Adolescents with Rheumatic Disease: Racial and Ethnic Diversity by Texas County
Kristina Ciaglia¹, Chan-hee Jo², Yuhan Ma², Tracey Wright³ and Lorien Nassi¹, ¹University of Texas Southwestern, Dallas, TX, ²Scottish Rite Hospital for Children, Dallas, TX, ³University of Texas Southwestern, Scottish Rite Hospital for Children, Dallas, TX
Background/Purpose: Rheumatic disease disproportionately impacts specific racial and ethnic groups frequently, resulting in health care inequities. Health care disparities are prevalent within certain geographic areas…
Abstract Number: 128 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children and Systemic Juvenile Idiopathic Arthritis Share Clinical Phenotypes and Genetic Contributions
Paul Tsoukas¹, Hua Lu², Marla Mendes de Aquino², Michael Ombrello³, Lisa Strug² and Rae Yeung⁴, ¹The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, North Bethesda, MD, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a novel clinical entity presenting following SARS CoV2 infection. This study describes a subgroup of MIS-C patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].